TY - JOUR
T1 - Clear cell renal cell carcinoma ontogeny and mechanisms of lethality
AU - Jonasch, Eric
AU - Walker, Cheryl Lyn
AU - Rathmell, W. Kimryn
N1 - Publisher Copyright:
© 2020, Springer Nature Limited.
PY - 2021/4
Y1 - 2021/4
N2 - The molecular features that define clear cell renal cell carcinoma (ccRCC) initiation and progression are being increasingly defined. The TRACERx Renal studies and others that have described the interaction between tumour genomics and remodelling of the tumour microenvironment provide important new insights into the molecular drivers underlying ccRCC ontogeny and progression. Our understanding of common genomic and chromosomal copy number abnormalities in ccRCC, including chromosome 3p loss, provides a mechanistic framework with which to organize these abnormalities into those that drive tumour initiation events, those that drive tumour progression and those that confer lethality. Truncal mutations in ccRCC, including those in VHL, SET2, PBRM1 and BAP1, may engender genomic instability and promote defects in DNA repair pathways. The molecular features that arise from these defects enable categorization of ccRCC into clinically and therapeutically relevant subtypes. Consideration of the interaction of these subtypes with the tumour microenvironment reveals that specific mutations seem to modulate immune cell populations in ccRCC tumours. These findings present opportunities for disease prevention, early detection, prognostication and treatment.
AB - The molecular features that define clear cell renal cell carcinoma (ccRCC) initiation and progression are being increasingly defined. The TRACERx Renal studies and others that have described the interaction between tumour genomics and remodelling of the tumour microenvironment provide important new insights into the molecular drivers underlying ccRCC ontogeny and progression. Our understanding of common genomic and chromosomal copy number abnormalities in ccRCC, including chromosome 3p loss, provides a mechanistic framework with which to organize these abnormalities into those that drive tumour initiation events, those that drive tumour progression and those that confer lethality. Truncal mutations in ccRCC, including those in VHL, SET2, PBRM1 and BAP1, may engender genomic instability and promote defects in DNA repair pathways. The molecular features that arise from these defects enable categorization of ccRCC into clinically and therapeutically relevant subtypes. Consideration of the interaction of these subtypes with the tumour microenvironment reveals that specific mutations seem to modulate immune cell populations in ccRCC tumours. These findings present opportunities for disease prevention, early detection, prognostication and treatment.
UR - http://www.scopus.com/inward/record.url?scp=85094874760&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85094874760&partnerID=8YFLogxK
U2 - 10.1038/s41581-020-00359-2
DO - 10.1038/s41581-020-00359-2
M3 - Review article
C2 - 33144689
AN - SCOPUS:85094874760
SN - 1759-5061
VL - 17
SP - 245
EP - 261
JO - Nature Reviews Nephrology
JF - Nature Reviews Nephrology
IS - 4
ER -